Literature DB >> 21660412

Efficient generation of useful monoclonal antibodies reactive with globotriaosylceramide using knockout mice lacking Gb3/CD77 synthase.

Yuji Kondo1, Noriyo Tokuda, Keiko Furukawa, Reiko Ando, Makoto Uchikawa, Qing Zhang, Fan Xiaoyan, Koichi Furukawa.   

Abstract

Efficient generation of useful monoclonal antibodies (mAbs) with high performance in cancer therapeutics has been expected. Generation of mAbs reactive with globotriaosylceramide (Gb3/CD77) was compared between A/J mice and Gb3/CD77 synthase-deficient (A4GalT-knockout) mice by immunizing Gb3-liposome. Specificity and functions of established antibodies were examined by ELISA, TLC- immunostaining, cytotoxicity of cancer cells and immunoblotting. Compared with results with conventional mice, better generation of mAbs with higher functions has been achieved with A4GalT-knockout mice, i.e. acquisition of IgG class antibodies, activities in antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and aggregation activity toward a Burkitt's lymphoma line Ramos. Binding of mAb k52 induced tyrosine phosphorylation of several proteins in Ramos cells. One of the strongest phosphorylation bands turned out to be c-Cbl. Pretreatment of B cell lines with mAbs resulted in the attenuation of BCR-mimicking signaling. All these results suggested that A4GalT-knockout mice are very useful to generate mAbs against globo-series glycolipids, and that suppressive signaling pathway driven by endogenous Gb3-ligand molecules might be present in B cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21660412     DOI: 10.1007/s10719-011-9335-4

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  35 in total

Review 1.  The Cbl protooncoprotein: a negative regulator of immune receptor signal transduction.

Authors:  M L Lupher; N Rao; M J Eck; H Band
Journal:  Immunol Today       Date:  1999-08

Review 2.  Monoclonal antibodies.

Authors:  P N Nelson; G M Reynolds; E E Waldron; E Ward; K Giannopoulos; P G Murray
Journal:  Mol Pathol       Date:  2000-06

3.  The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer.

Authors:  Olga Kovbasnjuk; Rakhilya Mourtazina; Boris Baibakov; Thomas Wang; Christian Elowsky; Michael A Choti; Anne Kane; Mark Donowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 4.  c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses.

Authors:  Christine B F Thien; Wallace Y Langdon
Journal:  Biochem J       Date:  2005-10-15       Impact factor: 3.857

Review 5.  Hybridomas: a new dimension in biological analyses.

Authors:  R H Kennett
Journal:  In Vitro       Date:  1981-12

6.  The blood group P1 synthase gene is identical to the Gb3/CD77 synthase gene. A clue to the solution of the P1/P2/p puzzle.

Authors:  Koichi Iwamura; Keiko Furukawa; Makoto Uchikawa; Birgitta Nilsson Sojka; Yoshinao Kojima; Joelle Wiels; Hiroshi Shiku; Takeshi Urano; Koichi Furukawa
Journal:  J Biol Chem       Date:  2003-07-29       Impact factor: 5.157

7.  Generation of one set of monoclonal antibodies specific for b-pathway ganglio-series gangliosides.

Authors:  H Ozawa; M Kotani; I Kawashima; T Tai
Journal:  Biochim Biophys Acta       Date:  1992-01-24

8.  Innate murine B cells produce anti-disialosyl antibodies reactive with Campylobacter jejuni LPS and gangliosides that are polyreactive and encoded by a restricted set of unmutated V genes.

Authors:  Judith Boffey; Dawn Nicholl; Eric R Wagner; Kate Townson; Carl Goodyear; Keiko Furukawa; Koichi Furukawa; Joe Conner; Hugh J Willison
Journal:  J Neuroimmunol       Date:  2004-07       Impact factor: 3.478

9.  Analysis of the specificity of five murine anti-blood group A monoclonal antibodies, including one that identifies type 3 and type 4 A determinants.

Authors:  K Furukawa; H Clausen; S Hakomori; J Sakamoto; K Look; A Lundblad; M J Mattes; K O Lloyd
Journal:  Biochemistry       Date:  1985-12-17       Impact factor: 3.162

10.  Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide.

Authors:  M Jacewicz; H Clausen; E Nudelman; A Donohue-Rolfe; G T Keusch
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  5 in total

1.  Immunization of A4galt-deficient mice with glycosphingolipids from renal cell cancers resulted in the generation of anti-sulfoglycolipid monoclonal antibodies.

Authors:  Reiko Ando; Noriyo Tokuda; Tokunori Yamamoto; Kazutaka Ikeda; Noboru Hashimoto; Ryo Taguchi; Xiaoen Fan; Keiko Furukawa; Yukio Niimura; Akemi Suzuki; Momokazu Goto; Koichi Furukawa
Journal:  Glycoconj J       Date:  2016-02-16       Impact factor: 2.916

2.  Recent advances of sonodynamic therapy in cancer treatment.

Authors:  Guo-Yun Wan; Yang Liu; Bo-Wei Chen; Yuan-Yuan Liu; Yin-Song Wang; Ning Zhang
Journal:  Cancer Biol Med       Date:  2016-09       Impact factor: 4.248

3.  Comparative analysis of antigen coding genes in 15 red cell blood group systems of Yunnan Yi nationality in China: A cross-sectional study.

Authors:  Kun-Hua He; Lu-Qiong Xu; Ying-Feng Hu; Yin-Xia Xu; Yu Zhao; Jing-Yan Bao; Bu-Qiang Wang
Journal:  Health Sci Rep       Date:  2022-10-17

4.  Anti-Gb3 monoclonal antibody inhibits angiogenesis and tumor development.

Authors:  Ariane Desselle; Tanguy Chaumette; Marie-Hélène Gaugler; Denis Cochonneau; Julien Fleurence; Nolwenn Dubois; Philippe Hulin; Jacques Aubry; Stéphane Birklé; François Paris
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

5.  Deletion of Gb3 Synthase in Mice Resulted in the Attenuation of Bone Formation via Decrease in Osteoblasts.

Authors:  Kazunori Hamamura; Kosuke Hamajima; Shoyoku Yo; Yoshitaka Mishima; Koichi Furukawa; Makoto Uchikawa; Yuji Kondo; Hironori Mori; Hisataka Kondo; Kenjiro Tanaka; Ken Miyazawa; Shigemi Goto; Akifumi Togari
Journal:  Int J Mol Sci       Date:  2019-09-18       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.